Proactive Investors - GSK (LON:GSK) has delivered encouraging updates from ongoing trials of its vaccines for Shingles and Gonorrhoea.
In the follow-up Zoster trial for the now on-sale Shingrix vaccine, efficacy was more than 80% for patients over 50 between 6-11 years after the jab with no new safety issues identified.
Phil Dormitzer, GSK’s head of vaccines R&D, said: "These data go far beyond the typical long-term follow-up period for a trial, tracking the efficacy of vaccination for some participants as they aged into their 70s, 80s and 90s.
“With the vaccine now included in many national immunisation programmes around the world, these data add to the body of evidence on the extended long-term protection against shingles and provide further confidence to inform public immunisation strategies."
Gonorrhoea treatment Gepotidacin, meanwhile, achieved a 92.6% microbiological success rate and was non-inferior to the leading combination treatment in the EAGLE-1 phase III trial, which GSK said was the third positive for the treatment as a potential oral antibiotic.
Results from the trial will be presented at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global.
Chris Corsico, SVP Development, at GSK, said: "These results highlight the potential of gepotidacin as a new oral treatment option given the rising incidence of gonorrhoea worldwide including drug-resistant infections.
“The imperative for innovative treatments has never been clearer. We are committed to working with health regulators globally to introduce this potential new antibiotic, focusing on solutions that meet critical patient needs."
GSK is also developing gepotidacin as a potential treatment of uncomplicated urinary tract infections (uUTI).
Shares eased 0.8^ to 1,597p.